|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| |  |  | | --- | --- | | |  | | --- | |  | | | |  | | --- | |  | | PSNC Newsletter | | Friday 13th January 2023 | | |  | | |  |  |  | | --- | --- | --- | |  |  |  | |  | This newsletter from PSNC is sent on Mondays, Wednesdays and Fridays. It contains important information for those that work in the community pharmacy sector. In this update: Minister comments on pharmacy funding; Data Security and Protection Toolkit guidance; dispensing and supply updates.Minister comments on additional funding plea for pharmacy In a statement to the House of Lords on Tuesday, Lord Markham, a Health Minister, talked about a ‘plan of using [pharmacies] more for patients [that] will put more funding their way’. He also went on to praise the sector saying that they are a ‘crucial part of the front line’.  Lord Markham was responding to a question from Lord Grade, who is campaigning on behalf of community pharmacy and in contact with PSNC.  We are continuing to work to brief Ministers, MPs and the Opposition and in recent weeks we have seen a number of MPs and Peers speaking out in support of community pharmacy. In the coming weeks we will launch the Pharmacy Pressures Survey which will give all contractors and their teams the chance to feed in vital data to support our influencing work and case to Government.  [**Find out more about Lord Markham's comments**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=e181ecfd42&e=d19e9fd41c) Data Security and Protection Toolkit guidance PSNC has published new guidance to help community pharmacy contractors to complete the 2022/23 Data Security and Protection Toolkit. The Toolkit is used to make a pharmacy’s information governance (IG) declaration and the deadline for completion is **Friday 30th June 2023**.  PSNC collaborated with NHS Digital to keep the workload associated with Toolkit completion manageable and published our guidance materials as soon as was practicable. Contractors are advised to read the guidance and consider the Toolkit in their workload planning.   [**Read our new Toolkit guidance**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=c69fff9e3f&e=d19e9fd41c) Dispensing and Supply Updates **Five SSPs further extended and expiry of Lenzetto SSPs** The following Serious Shortage Protocols (SSPs) have been further extended until **Friday 27th January 2023**.   * [**SSP029 Sandrena® 0.5mg and 1mg gel sachets – restriction**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=6c6d9232d5&e=d19e9fd41c) * [**SSP030 Sandrena® 0.5mg and 1mg gel sachets –  substitution**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=da0aeeaa76&e=d19e9fd41c) * [**SSP031 Sandrena® 0.5mg and 1mg gel sachets –  substitution and restriction**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=597dbef7ca&e=d19e9fd41c) * [**SSP036 Estraderm MX® 100mcg patches**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=bbed8f460f&e=d19e9fd41c) * [**SSP038 Estraderm MX® 75mcg patches**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=379fb30801&e=d19e9fd41c)   The below SSPs are also set to expire at **23.59 today (Friday 13th January)**:   * [**SSP026 Lenzetto®1.53mg/dose transdermal spray –  restriction**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=17c2f91310&e=d19e9fd41c) * [**SSP027 Lenzetto®1.53mg/dose transdermal spray –  substitution**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=d70d51d7b6&e=d19e9fd41c) * [**SSP028 Lenzetto®1.53mg/dose transdermal spray – substitution and restriction**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=4feab305b8&e=d19e9fd41c)   Following the expiry of the above SSPs, any prescriptions for Lenzetto® 1.53mg/dose transdermal spray must be dispensed in accordance with the prescription. [**Learn more**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=ca25990dc8&e=d19e9fd41c).  **Company-led medicines recall** The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a company-led medicines recall for Fluphenazin-neuraxpharm® D 25 & 100 mg/ml Solution for Injection. Specified batches of this product are being recalled by the manufacturer, Mawdsley-Brooks and Company Limited, as a precautionary measure due to out of specification test results.   Contractors should quarantine stock of the relevant batches and return them to the manufacturer as soon as possible. [**Find out more**](https://psnc.us7.list-manage.com/track/click?u=86d41ab7fa4c7c2c5d7210782&id=42c2f6e8dc&e=d19e9fd41c) |  | |  |  |  | | |
| |  |  |  | | --- | --- | --- | | |  | | --- | | Pharmaceutical Services Negotiating Committee      14 Hosier Lane, London, EC1A 9LQ Tel: 0203 1220 810 | Email: [**info@psnc.org.uk**](mailto:info@psnc.org.uk) | |  | | |

